Myriad Genetics announced the launch of UroSuite, a comprehensive suite of genetic risk assessment tests that cover every stage of prostate cancer care. UroSuite includes Myriad’s Prolaris Prostate Cancer Test, MyRisk Hereditary Cancer Test, BRACAnalysis CDx and Precise Tumor Molecular Profile Test. The combination of tests provides integrated genetic insights and makes it easier to tailor therapy and clinical trial selection for patients. "Today’s launch of UroSuite reinforces Myriad Genetics’ commitment to advancing health and well-being for all through a set of testing solutions for prostate cancer care, best-in-class support, and access to genetics and cancer specialists," said Paul J. Diaz, president and CEO, Myriad Genetics. "We continue to build on our efforts to elevate our products to their full potential and introduce new innovative solutions and analytics to help patients and healthcare providers with personalized genetic insights and data-driven medical information."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MYGN:
- Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information
- New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries
- Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test
- Myriad Genetics Reports Third Quarter Financial Results
- Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member
